Skip to content
OpenCapital
Get started

Collegium Pharmaceutical, Inc. COLL Q3 2025 earnings

Reported November 6, 2025 · Before market open

Revenue$209.4MBeat by $3.2M
EPS$2.25Beat by $0.39
Revenue estimate$206.2M
EPS estimate$1.86

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$199.6M
EPS estimate$1.68

Financials

Q3 2025

Income statement

See full
Revenue$209.4M+31.4%
Gross profit$129.2M+33.4%
Operating income$62.1M+78.2%
Net income$31.5M+238%
EPS (diluted)$0.84+211%

Balance sheet

See full
Cash & equivalents$150.1M+285%
Total debt$5.9M-18.3%
Total equity$274.8M+17.3%
Total assets$1.6B-1.7%

Cash flow

See full
Operating cash flow$78.4M—
CapEx$188.0K-23.0%
Free cash flow$78.3M—

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.1B-11.4%
Enterprise value$958.04M-21.0%
P/E18.9×+4.8×
P/S1.5×-0.6×

Profitability

See full
Gross margin57.2%-5.1pp
Operating margin20.7%-11.5pp
Net margin7.7%-7.1pp
FCF margin38.2%+4.6pp

Returns & leverage

See full
Return on equity23%-19.9pp
Debt / equity0×0.0×
Current ratio1.4×+0.4×

Segments

By product

See full
Belbuca$58.3M+9.5%
Jornay PM$41.8M+425%
Nucynta IR$32.0M+26.1%
Nucynta ER$22.8M+15.4%
Symproic$4.0M+14.4%

By segment

See full
Segment$209.4M+31.4%

Versus estimates

Revenue

Q1 2026$193.5MBeat by $9.0MQ4 2025$205.4MMiss by $913.4K
Q3 2025$209.4MBeat by $3.2M
Q2 2025$188.0MMiss by $3.3MQ1 2025$177.8MBeat by $4.7MQ4 2024$181.9MBeat by $2.3M

Diluted EPS

Q1 2026$1.76Beat by $0.24Q4 2025$2.04Miss by $0.10
Q3 2025$2.25Beat by $0.39
Q2 2025$1.68Beat by $0.06Q1 2025$1.49Beat by $0.06Q4 2024$1.77Beat by $0.23

Ask the moment Collegium Pharmaceutical, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Collegium Pharmaceutical, Inc. report Q3 2025 earnings?
Collegium Pharmaceutical, Inc. (COLL) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Collegium Pharmaceutical, Inc.'s Q3 2025 revenue and EPS?
Collegium Pharmaceutical, Inc. reported revenue of $209.4M and eps of $2.25 for Q3 2025.
Did Collegium Pharmaceutical, Inc. beat estimates in Q3 2025?
Revenue beat the consensus estimate of $206.2M by $3.2M. EPS beat the consensus estimate of $1.86 by $0.39.
How did Collegium Pharmaceutical, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 31.4% from $159.3M a year earlier and eps grew 39.8% from $1.61.
Where can I find Collegium Pharmaceutical, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-107389) and the 10-Q periodic report (0001104659-25-107391) directly on SEC EDGAR. The filing index links above go to sec.gov.